Articles tagged with Chemotherapy
Researchers developed a nanosponge-based delivery system that is three to five times more effective than direct injection in reducing tumor growth. The system uses biodegradable particles with predictable release characteristics, making it an attractive alternative for targeted cancer therapy.
A study published in The Lancet Oncology found that zoledronic acid reduced the number of tumor cells in bone marrow at surgery and improved bone density in women with stage II or III breast cancer. The treatment may also help fight certain types of breast tumors directly.
A study published in the American Society of Clinical Oncology annual meeting showed that lenalidomide significantly improved response rates and complete remission in patients with transformed lymphoma. Patients treated with lenalidomide had a remarkable response rate, with some experiencing complete remission for over a year.
Erlotinib maintenance therapy significantly improves progression-free and overall survival in patients with non-small-cell lung cancer. The treatment is generally well-tolerated, with mild to moderate side effects.
Patients who undergo gastric cancer surgery followed by chemotherapy have a lower risk of death and improved disease-free survival compared to those who receive surgery alone. The analysis found an 18% reduction in the risk of death and improved overall survival with chemotherapy.
A recent study by American Academy of Pediatrics found that parents administering medication to children with chronic conditions often make mistakes. The researchers visited the homes of 83 children and reviewed 544 medications, discovering 128 errors, including those that could injure the child.
A Phase I trial combining pemetrexed with radiation and chemotherapy for stage III non-small-cell lung cancer demonstrates tolerability and efficacy. The regimen allows high cytotoxic doses during radiotherapy, increasing the chance of killing cancerous cells.
Researchers found that combining regional hyperthermia with chemotherapy increases local progression-free and disease-free survival rates in high-risk sarcoma patients. The treatment has shown promise, but the safety profile remains a concern.
The ERCC1 Analysis measures ERCC1 levels in cells to predict response to cisplatin-based chemotherapy, which is considered the standard of care for advanced NSCLC. Studies have shown that low expression levels of ERCC1 are related to a better response and survival benefit from adjuvant cisplatin-based chemotherapy.
Researchers found that zoledronic acid decreased detectable tumour cells in women with locally advanced breast cancer, particularly after 3 months of treatment. The study suggests zoledronic acid's potential to alter the microenvironment making it less favourable for cancer cells.
The study found that PARP expression is present in all breast cancer subtypes and correlates with a total response to chemotherapy. Tumors with high PARP levels showed a significant improvement in overall survival.
New research suggests that pregnant women with breast cancer can be treated with chemotherapy without endangering the health of their unborn baby. The study found that babies exposed to chemotherapy during pregnancy were born slightly lighter but otherwise had similar outcomes as those not exposed to chemotherapy.
Adding chemotherapy to surgery or surgery plus radiotherapy significantly improves survival rates for patients with operable non-small-cell lung cancer. The meta-analysis found a 4% increase in survival at 5 years, regardless of the type of chemotherapy used.
A new study found that older patients with stage III colon cancer are less likely to receive chemotherapy after surgery due to concerns about adverse events. However, the study discovered that when they do receive chemotherapy, it is less toxic and of shorter duration compared to younger patients, resulting in fewer adverse events.
Researchers have found a way to enhance drug delivery to solid tumors by temporarily breaking down blood vessel walls, allowing drugs to reach the tumor more efficiently. This breakthrough could lead to improved treatment options for previously intractable solid cancers.
Researchers found that microRNA-31 regulates the protein IFITM-1, which contributes to chemoresistance in ovarian cancer. Identifying this microRNA could lead to a therapeutic target for overcoming chemotherapy resistance.
Research found no significant differences in tolerance and efficacy between elderly and non-elderly NSCLC patients receiving salvage targeted therapy or chemotherapy. Elderly patients showed comparable response rates, disease control, and survival times as younger patients.
Aprepitant has been shown to dramatically reduce nausea and vomiting in bone marrow transplant patients, with 73% experiencing no vomiting and 49% having little or no nausea. This breakthrough finding suggests aprepitant could become a standard part of patients' care.
Researchers identify a gene signature that predicts colon cancer recurrence and death, allowing for personalized chemotherapy targeting and avoiding toxic treatments.
Researchers have developed a nanotechnology approach that allows for targeted and simultaneous delivery of cancer-killing drugs and genetic drugs to prevent resistance. The treatment shows promise in eliminating side effects associated with chemotherapy.
A research team led by Dr. Velusamy Rangasamy and Dr. Ajay Rana has identified a key protein that can serve as a target for estrogen-receptor positive breast cancer treatment. This finding could lead to the development of more targeted therapies to improve chemotherapy effectiveness.
Scientists created oil droplets that can solve complex mazes using pH gradients, potentially helping cancer drugs reach tumors and nano-machines move accurately. This technology could be used to design new anti-cancer drugs and improve the navigation of futuristic nano-machines.
A new multi-targeted treatment regimen combining chemotherapy and targeted drugs improves progression-free survival and tumour response in patients with metastatic renal-cell carcinoma. The study found a clinical benefit rate of over 90% with manageable side effects.
Researchers found that Herceptin significantly improved event-free survival in patients with HER2-positive locally advanced or inflammatory breast cancer, with a 3-year event-free survival rate of 71% compared to 56%. The treatment was well-tolerated, with only two patients experiencing symptomatic cardiac failure.
A combined chemotherapy regimen of capecitabine and oxaliplatin given before chemoradiotherapy and surgery is well tolerated and shows promising anti-tumour activity in patients with poor-risk rectal cancer. The treatment improves overall survival rates, with 68% of patients progression-free after 3 years.
Evolutionary theory is being applied to various medical questions, from aging and mental illnesses to cancer and antibiotic resistance. Future physicians may face tests on evolution, with increased emphasis on incorporating evolutionary concepts into medical practice.
Phase II study results of ASA404 showed improved overall survival in patients with squamous and non-squamous NSCLC compared to chemotherapy alone. The drug's unique mechanism of action inhibits tumor blood flow, providing a potential new treatment option for limited options.
A new 21-gene test is helping doctors and patients make informed treatment decisions by predicting whether chemotherapy is necessary for early-stage breast cancer. The test, which examines tumor gene activity, has led to changes in treatment recommendations in 31.5% of cases, with most changes favoring avoidance of chemotherapy.
A U-M study reveals that a specific receptor, CXCR1, triggers growth of breast cancer stem cells in response to inflammation and tissue damage. Researchers found that blocking this receptor using an existing anti-inflammatory drug repertaxin kills breast cancer stem cells and prevents metastasis in mice.
Researchers have found that figitumumab has antitumor activity in Ewing's sarcoma, a cancer commonly affecting male teenagers. The drug targets the insulin-like growth factor signalling pathway, and initial studies have shown safety and efficacy in patients with refractory Ewing's sarcoma.
Researchers at UCLA's Jonsson Comprehensive Cancer Center discovered that deoxycytidine kinase (dCK) enzyme plays a crucial role in the development of healthy immune systems. Mice without this enzyme have defects in their adaptive immune system, producing very low levels of T and B lymphocytes.
Patients with NSCLC and EGFR mutations showed significantly improved progression-free survival with gefitinib treatment. Gefitinib was also better tolerated than chemotherapy, with fewer severe adverse events.
Researchers developed an animal model showing four commonly used chemotherapy drugs disrupt new brain cell birth and that IGF-1 may partially reverse the condition. The study is relevant to cancer survivors experiencing cognitive decline after chemotherapy.
A group of heart drugs, cardiac glycosides, have been found to be effective against human colon cancer cells, with varying degrees of sensitivity. The findings suggest that these heart drugs could potentially improve colon cancer outcomes when used alone or in combination with conventional chemotherapy.
Using Herceptin with chemotherapy reduces the risk of cancer recurrence by 25% compared to using it after chemotherapy. This new standard of care may benefit up to 10,000 women worldwide each year.
A phase 3 trial found that adding chemotherapy to tamoxifen treatment significantly improves disease-free survival in postmenopausal women with node-positive breast cancer. The benefit is maximized when tamoxifen follows chemotherapy.
A landmark study confirms that chemotherapy with tamoxifen improves survival rates for postmenopausal women with estrogen receptor-positive breast cancer. A second study identifies a subset of patients who may not benefit from chemotherapy despite being at higher risk, suggesting a potential need to reassess treatment guidelines.
A landmark study by Dr. Kathy Albain of Loyola University Health System found that chemotherapy improves survival in postmenopausal breast cancer patients, while a multigene test can identify those who may not benefit from chemotherapy. The study established the standard of care for tamoxifen treatment in relation to chemotherapy.
Researchers at Dana-Farber Cancer Institute found that midostaurin, a kinase inhibitor targeting FLT3 cell receptor, combined with chemotherapy reduced circulating leukemia cells in AML patients. Complete responses occurred in 80% of patients with mutated FLT3, and high survival rates were observed one and two years after treatment.
Researchers analyzed CT scans of 50 surgical patients with metastatic colorectal cancer to predict overall survival. The findings showed that morphologic changes on CT images correlated with pathologic response and improved survival.
A study found that morphologic changes on CT scans after bevacizumab-containing chemotherapy can predict overall survival in patients with stage IV colorectal cancer. The changes, including tumor size reduction and unique structural alterations, were strongly correlated with pathologic response and improved survival.
A new study found that long-term testicular cancer survivors who received cisplatin-based chemotherapy experienced more severe neurological side effects compared to those not treated with chemotherapy. The study suggests that dose-intensive chemotherapy regimens can limit ototoxicity and hearing impairment in these patients.
A phase 2 trial investigates the effectiveness of a combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) plus bevacizumab in treating advanced biliary-tract cancers, showing an overall response rate of 40% and stable disease in 29%. Whole-body PET scans show promising results for monitoring treatment response.
The editorial highlights exaggerated fears and hopes in media coverage of cancer research, such as uncontrolled study results and unwarranted fear from studies. Journalists can alleviate this problem by asking the right questions, highlighting study limitations, and providing data to support claims.
Researchers have developed a new mouse variety that approximates human genetic diversity, allowing for more accurate testing of chemotherapeutic drugs. The study aims to reduce the risk of adverse reactions and improve treatment outcomes for cancer patients.
A recent study found that adding capecitabine to a standard chemotherapy regimen for breast cancer improves recurrence-free survival, but at the cost of increased adverse events. The treatment was associated with more cases of diarrhea and hand-foot syndrome, while also causing more severe neutropenia.
Scientists at Michigan State University are using a $3 million NIH grant to study the synthesis of medicinal compounds in popular plants. The goal is to understand how genes contribute to this process, leading to cheaper and more effective drug development.
A review of nearly 150 papers found that tinnitus causes significant distress, with many patients told nothing can be done to alleviate symptoms. The researchers advocate for increased support, guidance, and treatment options for those affected.
Researchers at Duke University have developed a simple and inexpensive method for loading cancer drugs into nano-scale delivery vehicles. The new formulation showed promising results in animal models, eliminating tumors after a single treatment while reducing side effects associated with systematic chemotherapy.
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
Combining chemotherapy with radiotherapy more than doubles event-free survival for patients with locally advanced head and neck cancer without prior surgery. Non-platinum-based chemotherapy shows long-term benefit with lower toxicity compared to platinum therapies.
Researchers found that leukemia cells reliant on MCL-1 are more sensitive to chemotherapeutic drugs than those dependent on BCL-2. A block in apoptosis selected during oncogenesis can significantly impact cancer's response to chemotherapy.
A team of University of Alberta researchers successfully synthesized a natural substance called Palmerolide A, which shows exceptional potential to specifically treat melanoma. The potency of palmerolide is exceptional and may prove to be more effective with less toxicity than current chemotherapy approaches.
Research reveals that up to a quarter of testicular cancer survivors experience long-term neurological, hearing, and circulation problems, as well as a higher risk of secondary cancers. However, many survivors can successfully father children after treatment, with up to 80% successful pregnancies.
Researchers found that a multivariable prediction model can accurately identify patients at low risk of recurrence, allowing for reduced chemotherapy treatments without compromising patient outcomes. The study suggests personalized medicine approach could improve cancer treatment decisions.
A phase 2 study found that adding imatinib mesylate to regular chemotherapy increased three-year survival rates for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) from 30-35% to 87%. The drug was well-tolerated and showed no significant side effects.
Researchers at Northwestern University discovered a potent new chemotherapy cocktail that inhibits breast cancer cell invasion by half. The mix of dasatinib and doxorubicin targets the Src kinase enzyme, believed to play a key role in breast cancer metastasis.
A new approach to treating malignant brain tumors has been discovered, with chemotherapy alone proven to be just as effective as traditional radiation therapy. The study identified a key gene mutation called IDH1 that predicts a better prognosis for patients, regardless of treatment.
Masitinib targets mast cells and shows greater activity and selectivity against KIT than benchmark TKI imatinib. The study demonstrates masitinib's potential in treating KIT and PDGFR-dependent diseases, including various cancers, inflammatory diseases, and neurological indications.
A new study found that investing in colorectal cancer screening programs could reduce treatment costs by more than half. The study suggests that the increasing use of expensive cancer drugs will make screening programs more cost-effective, making them a desirable investment for governments and insurance companies.